Just 3% of the nation’s physicians and patients take part in clinical trial research that leads to new therapies, according to Food and Drug Administration (FDA) data.

On top of that, large academic health systems conduct most of the trials. That means they reach few medically underserved populations and that nonwhite populations participate at rates less than half of what their representation is in the general population.

But SiteBridge Research Inc.—recently spun out of Health2047, which is the wholly-owned innovation subsidiary of the AMA created to overcome systemic dysfunction in the U.S. health care system—plans to make clinical trials more accessible to community-based physician practices that traditionally haven’t had the resources they need to function as clinical trial sites.